297 related articles for article (PubMed ID: 38543693)
21. Human Papillomavirus Vaccine: The Cancer Prevention Moonshot.
Petrie K; Wells A; Eckert LO
Obstet Gynecol Clin North Am; 2023 Jun; 50(2):339-348. PubMed ID: 37149314
[TBL] [Abstract][Full Text] [Related]
22. [Expert consensus on immunoprophylaxis of human papillomavirus-related diseases (abridged)].
Vaccine and Immunization Branch, Chinese Preventive Medicine Association
Zhonghua Yu Fang Yi Xue Za Zhi; 2019 Dec; 53(12):1218-1235. PubMed ID: 31795578
[TBL] [Abstract][Full Text] [Related]
23. A Pan American Health Organization strategy for cervical cancer prevention and control in Latin America and the Caribbean.
Luciani S; Andrus JK
Reprod Health Matters; 2008 Nov; 16(32):59-66. PubMed ID: 19027623
[TBL] [Abstract][Full Text] [Related]
24. Prevalence and human papillomavirus (HPV) genotype distribution in Suzhou, China.
Wang T; Luan L; Deng J; Liu N; Wu Q; Gong T; Zhu J; Zhang Z; Zhang J
Hum Vaccin Immunother; 2023 Aug; 19(2):2241309. PubMed ID: 37519009
[TBL] [Abstract][Full Text] [Related]
25. Impact of scaled up human papillomavirus vaccination and cervical screening and the potential for global elimination of cervical cancer in 181 countries, 2020-99: a modelling study.
Simms KT; Steinberg J; Caruana M; Smith MA; Lew JB; Soerjomataram I; Castle PE; Bray F; Canfell K
Lancet Oncol; 2019 Mar; 20(3):394-407. PubMed ID: 30795950
[TBL] [Abstract][Full Text] [Related]
26. Implementation of HPV testing in Latin America.
Jeronimo J; Holme F; Slavkovsky R; Camel C
J Clin Virol; 2016 Mar; 76 Suppl 1():S69-S73. PubMed ID: 26699418
[TBL] [Abstract][Full Text] [Related]
27. Ten-year follow-up of human papillomavirus vaccine efficacy against the most stringent cervical neoplasia end-point-registry-based follow-up of
Lehtinen M; Lagheden C; Luostarinen T; Eriksson T; Apter D; Harjula K; Kuortti M; Natunen K; Palmroth J; Petäjä T; Pukkala E; Siitari-Mattila M; Struyf F; Nieminen P; Paavonen J; Dubin G; Dillner J
BMJ Open; 2017 Aug; 7(8):e015867. PubMed ID: 28821519
[TBL] [Abstract][Full Text] [Related]
28. Integration of human papillomavirus vaccination and cervical cancer screening in Latin America and the Caribbean.
Franco EL; Tsu V; Herrero R; Lazcano-Ponce E; Hildesheim A; Muñoz N; Murillo R; Sánchez GI; Andrus JK
Vaccine; 2008 Aug; 26 Suppl 11():L88-95. PubMed ID: 18945406
[TBL] [Abstract][Full Text] [Related]
29. Racial and Ethnic Group Knowledge, Perceptions and Behaviors about Human Papillomavirus, Human Papillomavirus Vaccination, and Cervical Cancer among Adolescent Females.
Bond SM; Cartmell KB; Lopez CM; Ford ME; Brandt HM; Gore EI; Zapka JG; Alberg AJ
J Pediatr Adolesc Gynecol; 2016 Oct; 29(5):429-435. PubMed ID: 26915922
[TBL] [Abstract][Full Text] [Related]
30. Pre-vaccine era cervical human papillomavirus infection among screening population of women in west Austria.
Borena W; Grünberger M; Widschwendter A; Kraxner KH; Marth E; Mayr P; Meier J; Ruth N; Guerrero AT; Marth C; Holm-von Laer D
BMC Public Health; 2016 Aug; 16(1):889. PubMed ID: 27565569
[TBL] [Abstract][Full Text] [Related]
31. Impact of human papillomavirus age-related prevalence and vaccination levels on interpretation of cervical screening modalities: a modelling study.
Grimes DR
BMJ Open; 2024 Feb; 14(2):e078551. PubMed ID: 38309749
[TBL] [Abstract][Full Text] [Related]
32. Prevalence and Distribution of Vaccine-Preventable Genital Human Papillomavirus(HPV) Genotypes in Ghanaian Women Presenting for Screening.
Donkoh ET; Asmah RH; Agyemang-Yeboah F; Dabo EO; Wiredu EK
Cancer Control; 2022; 29():10732748221094721. PubMed ID: 35536890
[TBL] [Abstract][Full Text] [Related]
33. Human papillomavirus epidemiology in populations with normal or abnormal cervical cytology or cervical cancer in the Middle East and North Africa: A systematic review and meta-analysis.
Obeid DA; Almatrrouk SA; Alfageeh MB; Al-Ahdal MNA; Alhamlan FS
J Infect Public Health; 2020 Sep; 13(9):1304-1313. PubMed ID: 32564935
[TBL] [Abstract][Full Text] [Related]
34. [Expert consensus on immunological prevention of human papillomavirus-related diseases].
Vaccine and Immunization Branch, Chinese Preventive Medicine Association
Zhonghua Yu Fang Yi Xue Za Zhi; 2019 Aug; 53(8):761-803. PubMed ID: 31378039
[TBL] [Abstract][Full Text] [Related]
35. [What should be known for the introduction of an HPV vaccine?].
Muñoz N; Jacquard AC
Presse Med; 2008 Oct; 37(10):1377-90. PubMed ID: 18786806
[TBL] [Abstract][Full Text] [Related]
36. Human papilloma virus (HPV) prophylactic vaccination: challenges for public health and implications for screening.
Adams M; Jasani B; Fiander A
Vaccine; 2007 Apr; 25(16):3007-13. PubMed ID: 17292517
[TBL] [Abstract][Full Text] [Related]
37. Human papillomavirus genotypic characteristics of 60,685 subjects under age-expansion vaccination of the nine-valent human papillomavirus vaccine: A cross-sectional study.
Liu Y; Li Z; Yuan L; Liu F; Wu K; Xiao X; Zhu C
J Infect Public Health; 2023 Jul; 16(7):989-995. PubMed ID: 37167646
[TBL] [Abstract][Full Text] [Related]
38. Characterization of human papillomavirus genotypes and their coverage in vaccine delivered to Ethiopian women.
Abate A; Munshea A; Nibret E; Alemayehu DH; Alemu A; Abdissa A; Mihret A; Abebe M; Mulu A
Sci Rep; 2024 Apr; 14(1):7976. PubMed ID: 38575600
[TBL] [Abstract][Full Text] [Related]
39. Prevalence of human papillomavirus genotypes among African women with normal cervical cytology and neoplasia: a systematic review and meta-analysis.
Ogembo RK; Gona PN; Seymour AJ; Park HS; Bain PA; Maranda L; Ogembo JG
PLoS One; 2015; 10(4):e0122488. PubMed ID: 25875167
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and other milestones for human papillomavirus vaccine introduction.
Pagliusi SR; Teresa Aguado M
Vaccine; 2004 Dec; 23(5):569-78. PubMed ID: 15630792
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
